26
Oct
2022

Biotech Executives Call for Action on Reproductive Health Rights

Shehnaaz Suliman, CEO, ReCode Therapeutics

Dear Friends and Biopharma colleagues, 

The rapidly approaching midterm elections carry the potential to dramatically reshape the political landscape in myriad ways. The importance of the US Supreme Court’s Dobbs decision in June, overturning Roe v. Wade, looms large. 

At this critical time, we must be clear that Dobbs was about more than abortion

Amanda Banks, MD

With the decision to eliminate a Constitutional right to abortion, a powerful few stripped a majority – women – of the right to make basic decisions affecting their healthcare and their lives. It marks the beginning of a broader loss of autonomy and privacy for all Americans.

As a result, in many states in our country, women no longer have the legal right to openly consult with their doctors, to make decisions informed by facts and receive the best care possible, without their actions subject to criminalization.

Julia Owens, CEO, Ananke Therapeutics

The impact of the Court’s ruling disproportionately affects the least powerful among us: the poor, the less educated, minority women, primarily in historically red states. 

The Dobbs decision undermines essential principles that underpin medical ethics, and that we as a healthcare industry hold as guiding principles: beneficence (doing good), non-maleficence (do no harm), autonomy (giving the patient the freedom to choose for themselves), and justice (ensuring fairness). 

Sheila Gujrathi, Executive Chair and Chair
Ventyx Biosciences, ImmPACT Bio, ADARx

Beyond abortion, this erosion of basic rights impacts miscarriage care, access to birth control and ironically fertility services, and this is just the beginning. As an industry dedicated to improving human health, we stand united in opposition to Dobbs and in support of people impacted by this decision.

In a July 2022 letter signed by hundreds of biotech leaders we emphasized that abortion is reproductive healthcare and denounced the Court’s decision. We emphasized that a woman’s decision to be pregnant or unpregnant are fundamental rights and personal choices.

Today we ask our industry to support four calls to action:

  1. Provide financial support and time off to employees who need to travel to obtain reproductive healthcare services.
  2. For any medicine that has been approved as safe and effective by the FDA for abortion care, treatment of miscarriage, or prevention of pregnancy, we call on FDA to work with sponsors to remove unnecessary barriers to access. Specifically, we call upon the FDA to remove the REMS restrictions for mifepristone, and to allow oral contraceptive pills to be sold over the counter. We commend FDA’s efforts to consider both actions.
  3. Any drug company that manufactures products used for abortion care, treatment of miscarriage, or prevention of pregnancy is called upon to make these medicines as widely accessible as possible.
  4. With the midterm elections upon us, we commit to making accommodations for our employees to take time off to vote.

We cannot, as an industry, or as a nation and regardless of gender, stay silent while our fundamental health rights are negated. By signing this letter, we as individuals and as organizations commit to these calls to action, and to maintaining continuous vigilance in our collective fight to improve human health for all.

The Biotech Sisterhood and Allies

 

Shehnaaz Suliman, MD

CEO

Recode Therapeutics

Amanda Banks, MD

Advisor, Board Member, Physician

 

 

Grace Colón, PhD

Former CEO

InCarda Therapeutics

Julia Owens

President & CEO

Ananke Therapeutics

Sheila Gujrathi, MD

Executive Chair and Chair

Ventyx Biosciences, ImmPACT Bio, ADARx

 

Paula Soteropoulos

Chairman

Ensoma

 

Rekha Hemrajani

CEO

Jiya Acquisition Corp

 

Sabrina Martucci Johnson

CEO

Daré Bioscience, Inc.

Peter Kolchinsky

Managing Partner

RA Capital Management, LP

Andrew Goldberg

COO
HealthVerity, Inc

 

Deborah Palestrant

Partner

5AM Ventures

Robert Poole 

Signatory

NW Biomedical Consulting Inc.

Julie Sunderland

Founder

Oriane Consulting

 

Catherine Riesen

VP, Finance

RA Ventures

 

Rita Balice-Gordon

CEO

Muna Therapeutics

Nina Kjellson

General Partner

Canaan

 

William Newell

CEO
Sutro Biopharma 

Nancy Whiting, PharmD

CEO

Recludix Pharma

Rosana Kapeller

President and CEO

ROME Therapeutics 

 

Amy Burroughs

CEO

Cleave Therapeutics

Jeffrey D. Marrazzo

Co-founder and former founding CEO, Spark Therapeutics

Marrazzo Ventures

 

Jeremy Levin, MD

Chairman and CEO
Ovid

 

Daphne Koller

CEO and Founder

Insitro

Martina Roos

CEO

Sardona

Alex Martin

CEO

Abcuro 

Samantha Miller

Co-founder and co-CEO

Cadence OTC Inc.

 

Ramona Doyle MD

Clinical Professor

UCSF

JeenJoo (JJ) Kang

CEO

Appia Bio

 

Cameron Pitt

CBO

Quanta Therapeutics

Art Krieg

Adjunct Professor

UMass Chan Medical School RNA Therapeutics Institute

 

Samantha S. Truex

CEO

Upstream Bio

 

Alex Harding, MD

SVP Business Development and Corporate Strategy

Remix Therapeutics

 

Wendye Robbins, MD

President & CEO

Blade Therapeutics, Inc.

Scott Wasserman

CEO

Latigo Biotherapeutics, Inc.

 

Ivana Magovcevic-Liebisch

CEO
Vigil Neuroscience

Jodie Morrison

Acting CEO and Board member

Q32

Sarah Boyce

CEO

Avidity 

 

Jennifer Beachell

COO

Upstream Bio 

 

Aoife Brennan

CEO

Synlogic

Peter Smith

CEO

Remix Therapeutics

 

 

Dave Melville

CEO

The Bowdoin Group

 

Carol L. Brosgart, MD

Clinical Professor of Medicine, Biostatistics and Epidemiology

UCSF

Kate Yen

CEO

Auron Therapeutics 

Nancy Stagliano

CEO

Neuron23 

Joanne Kotz

CEO

Jnana Therapeutics 

 

Yael Weiss

CEO

Mahzi Therpaeutics

 

Hanadie Yousef

CEO and co-founder

Juvena Therapeutics, inc. 

Alice Valder Curran

Partner

Hogan Lovells

Simone Azevedo

CEO

Xingu Health Inc

 

Karen Larochelle

CEO

LaRochelle Advisors, LLC

Tanya Joseph

Managing Director, Biotech Investment Banking

Cowen

 

Ramani Varanasi 

Managing Director

ReVive Advisors

 

Sarah Kurz

EVP

Partner Therapeutics

Blake Wise

CEO

Novome Biotechnologies

 

Shi Yin Foo

CEO

Arvada Therapeutics

 

Deborah S Kelly, MD

Executive Medical Director, Global Risk Mngt & Safety Surveillance

Incyte Corporation

 

Kristen Fortney

CEO and Co-founder

BioAge

Carol Marzetta 

Retired biopharma exec

Pfizer

 

Chris Conley

Biotech Consultant

DNA Consulting

Daniella Ishimaru

Principal Scientist

ReCode Therapeutics, Inc

Samantha S. Truex

CEO

Upstream Bio

 

Christine Zedelmayer

COO

Equillium, Inc. 

Andre Turenne

CEO

Matchpoint Therapeutics

Adam Keeney

CEO

NodThera

 

Kitty Wu

VP, Head of BD and Strategy 

Fosun Pharma USA

Laura Kahn

Executive director of R&D Strategy and Operations

ReCode Therapeutics

 

Erika Smith

CEO

ReNetX Bio

 

Richard Gaster

Managing Partner

venBio Partners

Eleanor Quin

Senior Director, Total Rewards and People

Totus Medicines

Pamela Michelle Klein, M.D.

Founder and Managing Director

PMK BioConsulting

Nathaniel Horwitz

President (Mayday) & Venture Partner (RA) 

Amber Brown

Chief of Staff

RA Capital

Karla Loken

Disease Area partner 

Roche

Laura Berner

COO

TRexBio

Donna Higgins

CEO

The Higgins Group Inc

 

Maria Fardis

Venture Partner

Frazier

 

Kenneth Drazan

Chairman & CEO

Arsenal Bio

Caryn Peterson

Partner

DSC Associates, LLC

Emily Drabant Conley

CEO

Federation Bio

 

Ashleigh Farver

Director

Biocom 

Jay Hagan

CEO

Regulus Therapeutics

Rajeev Shah

Managing Partner

RA Capital Management, LP

Cindy Xiong

Director

Foresite Capital 

 

Aaron Royston

Managing Partner

venBio Partners

Vickie Capps

Director

 

Michael Blash

Communications Consultant

BlashComm LLC

 

Ellen Lubman

Chief Business Officer and Head of Investor Relations

Werewolf Therapeutics, Inc.

 

Kelly C. Huang

Leadership/Executive Coach

Genesis Advisers

 

Elaine Sun

COO and CFO

Mammoth Biosciences

Clarissa Shen

COO and Board Member

Q Bio, Inc.

Shelia M. Violette

Chief Scientific Officer and Founder

Q32 Bio

 

Michael Saulnier

CFO

RA Capital

Bernat Olle

CEO

Vedanta Biosciences

Karl Kieburtz, MD, MPH

Managing Partner

Hoover Brown, LLC

Becki Filice

SVP, Portfolio and Program Leadership

CymaBay

 

Adam Rosenberg

CEO

Aliada Therapeutics

Rene Russo

CEO

Xilio Therapeutics

 

Sarah Reed

General Counsel

RA Capital Management

Mary Thistle

Director

Deborah Geraghty

CEO

Anokion

 

Safia K Rizvi

CEO

CILA Therapeutics, Inc.

Maria Soloveychik

CEO

SyntheX

 

Laure Nucci 

Executive Director, BD

Simcere 

 

Melissa Shaw

V.P., Legal and IP

Annexon, Inc.

Catherine Stehman-Breen

CEO

Chroma Medicine

Asina Gant

Division Counsel

Annexon Biosciences

 

 

Melita Sun Jung

Chief Business Officer

Structure Therapeutics Inc.

Jake Simson

Partner

RA Capital Management

 

Phyllis Loud Gray

SVP, Human Resources

Annexon Biosciences

 

Joseph O’Neill

Associate

RA Capital

Karpagam Srinivasan

Associate Director

Alector LLC

Jay Lichter

Managing Director

Avalon Ventures

 

Laura Stoppel

Principal

RA Capital

Cony D Cruz

Venture Partner

RA Ventures

Thomas Culman

Engagement Associate

RA Capital Management

 

Ernesto Gonzalez Jr.

Senior Business Systems Analyst

RA Capital

 

Fuad Naser

Associate

RA Capital Management

Alex Strasser

Associate

RA Capital Management

Daniel Slesinski

Associate

RA Capital Management

Megan Lipcsey

Healthcare associate, former physician

RA Capital

 

Edward Monaghan

Chief Development Officer

Lusaris Therapeutics, Inc.

 

Meghan Petrowski

Business Operations Manager / Recruiting Coordinator

RA Ventures

 

Cameron Decker

Research Assistant

RA Capital

Kaleen Sullivan

Sr Research Project Coordinator 

RA Capital

 

Jack Vailas

Senior Associate

RA Capital

Lauren Walrath

VP, Public Affairs

RA Capital

Jamie Donovan

Executive Assistant

RA Capital

Gunes Bozkurt

Venture Analyst

RA Capital

Simos Simeonidis

co-CEO/co-CIO, Managing Partner

Ally Bridge Group

 

Zach Scheiner

Principal

RA Capital

 

Nate Davis

Analyst

RA Capital

Emily Gransky

VP, Head of Recruiting

RA Capital

Anurag Kondapalli

Investor

RA Capital

Angela Pontius

VP, Clinical Operations

RA Capital

 

Julie Hambleton

Retired Pharma/Biotech Executive; Chief Medical Officer

Julie Krop

Chief Medical Officer, PureTech Health

 

Lori Rudolph-Owen

COO

Senda Biosciences

Diana Bernstein

VP

Northpond Ventures

Jasmine Ferrer

Managing Partner

Korn Ferry

 

Sharon Ayd

VP

Advarra

Ekaterine Kortkhonjia

Early Innovation Partnering

Johnson & Johnson

Jennifer Fang

Partner

Wilson Sonsini 

 

 

Aimee Raleigh

Sr Associate

Atlas Ventures

Alexander Martinez-Forte

Strategic Finance, Analyst

RA Capital

Matthew Hammond

Principal

RA Capital

 

 

Christina Lilliehook

Scientific Writer

RA Capital

Kate Moreau

Associate Director

RA Capital Management

 

Priya Patel

Business Development

Genentech

 

Gisela Paulsen

CEO

Oncocyte Corporation

Gina Patel

President and CEO

Patel Kwan Consultancy LLC

Joanne L Viney

CEO

Seismic Therapeutic

 

Scott Garland

CEO

PACT Pharma

Nerissa Kreher

Chief Medical Officer

Entrada Therapeutics

Sophie Chapelle

VP Corporate Development

Sherlock Biosciences

 

Monica Stanciu

Associate Director, TechAtlas

RA Capital

Kristine C. Mechem

VP Precision Medicine

Health Advances

Derek DiRocco

Partner

RA Capital Management

 

Monika Trzcinska 

Partner 

Bluestar Bioadvisors 

Kate Haviland

CEO

Blueprint Medicines

Cyriac Roeding

Co-founder, CEO

Earli Inc.

 

Lori Taylor

Executive

Annexon Biosciences

Emilie Besnard

Senior Scientist

Dorian Therapeutics 

Erez Chimovits 

Partner
OrbiMed

 

Cristina Montero

Associate Director

RA Capital, LP

Leslie J Williams

Founder President & CEO

hC Bioscience, Inc.

Kate Hermans

Interim CEO and President 

Ambrx

 

Harvey Chan

Controller

RA Capital

Bahija Jallal

CEO

Immunocore

Katherine Terranova

Healthcare Associate

RA Capital

 

Maria Radu

Principal Scientist

Merck

Robin Toft

Senior Advisor, Boardroom Diversity

ZRG Partners

 

Rebecca Silberman

Senior Associate

RA Capital

 

Hilary Malone

CEO

Certego Therapeutics

Catherine Flaherty

Executive Assistant

RA Capital

 

Sevgi Gurkan

Venture Partner and CEO

OrbiMed and Perfuse Therapeutics 

 

Nikole Kimes

CEO

Siolta Therapeutics, Inc.

 

Michael Varnum

Research Assistant

RA Capital

Mariagrace Houllahan

Executive Assistant

RA Capital Management

 

 

Akash Datwani

Director

Shikha Barman, PhD

Founder, President and CEO

Integral BioSystems

Saundra Pelletier

CEO

Evofem Biosciences

 

Dennis A. Dean, II

Principal Investigator

Seven Bridges

Rachel Bedenbaugh

Project Manager – Vaccines

RA Capital

Morgen Alden

Partner

FirstThought, LLC

 

James Schneider

Associate General Counsel

RA Capital

Rachel Haurwitz

President & CEO

Caribou Biosciences, Inc.

Maria Soloveychik

CEO

SyntheX

 

Angie You

Advisor

Frazier Healthcare and Casdin Capital

 

Dolca Thomas

Director; Board of Directors

Chinook

Elizabeth Aluck

Director Biopharma Partnering

Siemens Healthineers

 

Aetna Wun Trombley

CEO

Lycia Therapeutics

Sarah Bhagat

Biotech Investor

Yvonne Linney

Independent Board Member

Bionano Genomics

 

Bernard Coulie

President & CEO

Pliant Therapeutics

Kate Hermans

Interim CEO and President 

Ambrx

Alyssa Larson

Associate Director

RA Capital 

 

Amy DuRoss

Senior Advisor 

Frazier Healthcare Partners

Lauren La Rue

Head of Early CMC

GIVAX Inc. (Incubated under RA Capital Management)

 

David Carter Hoffman

Head of Intellectual Property

Bit Bio Inc.

 

Elaine Hamm

CEO

CLAIRIgene

Osvaldo Flores

CEO

Century Therapeutics

Katherine Vega Stultz

President and CEO 

Ocelot Bio

 

Alana McNulty

Director

Janux Therapeutics

Rhona O’Leary

Senior Vice President, Portfolio Strategy and Execution

Genentech

 

Liz Guthridge

Leadership coach

Connect Consulting Group

 

Michael Curtis

CEO

eGenesis

Florian Brand

CEO & Co-Founder

atai Life Sciences

Stephen Klasko

Executive in Residence

General Catalyst

 

Owen Richfield 

Postdoctoral Fellow

Yale University 

Smriti Jain

Project Manager

Consultant

Sibylle Hauser

Executive Director, Innovation & Entrepreneurship

CLS

 

Amy Lurier

SVP People and Talent

Carbon Biosviences

Jennifer Kane

Sr Director of PV

Arcus Biosciences

Susan Nemetz

CEO and Founder

The NemetzGroup LLC

 

Julie Martin Walker

Partner

Cramer

 

 

You may also like

An Open Letter from Female Biotech Leaders on Post-Roe America
Recode Therapeutics Pockets Extra $120M for Targeted Genetic Medicine Delivery